2010
DOI: 10.4161/cc.9.9.11347
|View full text |Cite
|
Sign up to set email alerts
|

Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
59
0

Year Published

2011
2011
2016
2016

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(60 citation statements)
references
References 62 publications
1
59
0
Order By: Relevance
“…Hence, the use of antagonists of GrP receptors represents a potential approach to inhibit the GrP-dependent effects on tumor growth. In this regard, it was demonstrated that the anti-tumor activity of GrP antagonists involves different mechanisms as the reduction of EGFR and Her2 levels, the alteration of MAPK, PKC, pAkt, and COX-2 signaling, the attenuation of c-fos and c-jun expression, the modulation of wild-type and mutated forms of p53 along with an alteration of Bcl-2/BAX ratio, the inhibition of vascular endothelial growth factor (VEGF) [47] . Radiolabeled GrP analogues represent another chance in targeting GrP receptors, thus they are currently considered promising radiopharmaceuticals for detection and treatment of different types of tumors [48,49] .…”
Section: Gpcrs Activated By Peptidesmentioning
confidence: 99%
See 1 more Smart Citation
“…Hence, the use of antagonists of GrP receptors represents a potential approach to inhibit the GrP-dependent effects on tumor growth. In this regard, it was demonstrated that the anti-tumor activity of GrP antagonists involves different mechanisms as the reduction of EGFR and Her2 levels, the alteration of MAPK, PKC, pAkt, and COX-2 signaling, the attenuation of c-fos and c-jun expression, the modulation of wild-type and mutated forms of p53 along with an alteration of Bcl-2/BAX ratio, the inhibition of vascular endothelial growth factor (VEGF) [47] . Radiolabeled GrP analogues represent another chance in targeting GrP receptors, thus they are currently considered promising radiopharmaceuticals for detection and treatment of different types of tumors [48,49] .…”
Section: Gpcrs Activated By Peptidesmentioning
confidence: 99%
“…In addition, ligand-stimulation of GrP receptors contributed to the growth of several malignancies through the activation of diverse phospholipases and protein kinases [47] . As GrP receptors were found overexpressed in a wide variety of tumors, their inhibition has been suggested as a promising objective in some malignancies [47] . Hence, the use of antagonists of GrP receptors represents a potential approach to inhibit the GrP-dependent effects on tumor growth.…”
Section: Gpcrs Activated By Peptidesmentioning
confidence: 99%
“…GRP is now recognized as the prototypical autocrine growth factor, based on the detection of GRP and its receptors in small cell lung carcinoma and other tumors (8). GRP was shown to stimulate growth of several other types of carcinomas including those of prostate, breast, colon, and pancreas (9). Three different receptor subtypes for the BN/GRP family of peptides have been described in mammals (10).…”
mentioning
confidence: 99%
“…Over the past 20 years, abundant evidence has been collected to suggest that GRP and its receptors play an important role in the development of a variety of cancers (Hohla and Schally, 2010). These observations have inspired researchers to find a suitable approach to treat cancers by taking advantage of blocking the GRP to GRPR signal pathway.…”
Section: Discussionmentioning
confidence: 99%